Premium
Cost‐Effectiveness of Pharmacogenetics‐Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
Author(s) -
Pink J,
Pirmohamed M,
Lane S,
Hughes D A
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.190
Subject(s) - apixaban , warfarin , dosing , medicine , rivaroxaban , dabigatran , pharmacogenetics , clinical trial , atrial fibrillation , intensive care medicine , pharmacology , biochemistry , chemistry , genotype , gene
Pharmacogenetics‐guided warfarin dosing is an alternative to standard clinical algorithms and new oral anticoagulants for patients with nonvalvular atrial fibrillation. However, clinical evidence for pharmacogenetics‐guided warfarin dosing is limited to intermediary outcomes, and consequently, there is a lack of information on the cost‐effectiveness of anticoagulation treatment options. A clinical trial simulation of S‐warfarin was used to predict times within therapeutic range for different dosing algorithms. Relative risks of clinical events, obtained from a meta‐analysis of trials linking times within therapeutic range with outcomes, served as inputs to an economic analysis. Neither dabigatran nor rivaroxaban were cost‐effective options. Along the cost‐effectiveness frontier, in relation to clinically dosed warfarin, pharmacogenetics‐guided warfarin and apixaban had incremental cost‐effectiveness ratios of £13,226 and £20,671 per quality‐adjusted life year gained, respectively. On the basis of our simulations, apixaban appears to be the most cost‐effective treatment. Clinical Pharmacology & Therapeutics (2014); 95 2, 199–207. doi: 10.1038/clpt.2013.190